Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments â MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.
Oxford Nanopore Facts
CEO: Gordon Sanghera
Ticker symbol: Privately held
Headquarters: Oxford, UK
Number of employees: 250+
Top Five Articles on 360Dx Last Week: Oxford Nanopore, BioMérieux Dx Deal; and More
Last week, readers were most interested in a story about a diagnostic deal between Oxford Nanopore and BioMérieux focused on infectious diseases.
The partnership, announced last week just before ECCMID kicked off, is the first major foray for both companies into the sequencing-based infectious disease diagnostics market.
Oxford Nanopore Technologies, BioMérieux to Develop Infectious Disease Diagnostics
Hoping to bring nanopore sequencing to the infectious disease market, the companies will first develop an IVD test for antibiotic-resistant tuberculosis.
Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay
The project will leverage Asuragen's long-range PCR and Oxford Nanopore's sequencing capabilities to develop a sequencing workflow for carrier screening.
The method, called DDNS, can identify poliovirus directly without cell culture, reducing the turnaround time for outbreak detection.